| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2022 | Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis | HSIANG-FONG KAO ; BIN-CHI LIAO ; YEN-LIN HUANG ; HUAI-CHENG HUANG ; Chun-Nan Chen ; TSENG-CHENG CHEN ; Hong, Yuan Jing; Chan, Ching Yi; JEAN-SAN CHIA ; RUEY-LONG HONG | Clinical Cancer Research | 20 | 19 | |
| 2012 | Aggressive revascularization of acute internal carotid artery occlusion in patients with NIHSS > 20 and poor collateral circulation: Preliminary report | Li A.-H.; Wang Y.-H.; HSIANG-FONG KAO ; Yang L.-H.; Chan L.; Chu S.-H.; HON-MAN LIU | International Journal of Cardiology | 4 | 4 | |
| 2014 | Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers | HSIANG-FONG KAO ; I-CHUN CHEN ; CHIUN HSU ; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN ; Hu F.-C.; CHIH-HSIN YANG ; ANN-LII CHENG ; KUN-HUEI YEH | Supportive Care in Cancer | 10 | 10 | |
| 2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | HSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Future Oncology | 7 | 6 | |
| 2018 | A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing | Lizotte P.H.; RUEY-LONG HONG ; Luster T.A.; Cavanaugh M.E.; Taus L.J.; Wang S.; Dhaneshwar A.; Mayman N.; Yang A.; Kulkarni M.; Badalucco L.; Fitzpatrick E.; HSIANG-FONG KAO ; Kuraguchi M.; Bittinger M.; Kirschmeier P.T.; Gray N.S.; Barbie D.A.; Janne P.A. | Cancer Immunology Research | 48 | 44 | |
| 2017 | Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma | Liu C.-W.; KUO-TAI HUA ; Li K.-C.; HSIANG-FONG KAO ; RUEY-LONG HONG ; JENG-YUH KO ; Hsiao M.; Kuo M.-L.; CHING-TING TAN | Molecular Cancer Therapeutics | 35 | 34 | |
| 2019 | Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions | HSIANG-FONG KAO ; Lou P.-J. | Head and Neck | 34 | 31 | |
| 2021 | Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma | SHIH-HUNG YANG ; LI-CHUN LU ; HSIANG-FONG KAO ; BANG-BIN CHEN ; TING-CHUN KUO ; SUNG-HSIN KUO ; YU-WEN TIEN ; Bai, Li-Yuan; ANN-LII CHENG ; KUN-HUEI YEH | Oncoimmunology | 1 | 2 | |
| 2013 | Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients | I-CHUN CHEN ; CHIUN HSU ; Chen Y.C.; Chien S.F.; HSIANG-FONG KAO ; Chang S.Y.; Hu F.C.; KUN-HUEI YEH | Annals of Oncology | 28 | 26 | |
| 2022 | Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis | HSIANG-FONG KAO ; HUAI-CHENG HUANG ; BIN-CHI LIAO ; RUEY-LONG HONG | BMC cancer | 2 | 2 | |
| 2014 | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Lee Y.-H.; MIN-SHU HSIEH ; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO ; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology (Switzerland) | 17 | 19 |
